Transform Pharmaceuticals to Present at UBS Global Life Sciences Conference.LEXINGTON, Mass. -- TransForm Pharmaceuticals, Inc. today announced that Paul D. Goldenheim, M.D., President, will be presenting at the UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. on Thursday, September 30, 2004. Dr. Goldenheim will present TransForm's business strategy and key accomplishments at the following time and location: Event: UBS Global Life Sciences Conference Date: Thursday, September 30, 2004 Time: 1:30 pm (EST) Location: The Grand Hyatt Hotel, New York City Audio: www.ibb.ubs.com The public is welcome to listen to the presentation through a UBS audio webcast. To do so, please visit www.ibb.ubs.com and click on Conferences. Follow the link for live audio under the Global Life Sciences Conference heading. The Presentation will be available live and by replay. About TransForm TransForm Pharmaceuticals is an emerging pharmaceutical company with distinctive proprietary technology to "transform" drugs for partners and our own proprietary product pipeline. We have demonstrated that significant clinical and commercial value can be harnessed by optimizing the form and formulation formulation /for·mu·la·tion/ (for?mu-la´shun) the act or product of formulating. American Law Institute Formulation of drugs both in development and those on the market. By understanding the value that physical-chemical properties play in developing the best drug possible, TransForm has created novel proprietary technologies that integrate physical chemistry and materials science materials science Study of the properties of solid materials and how those properties are determined by the material's composition and structure, both macroscopic and microscopic. with high-throughput parallel optimization optimization Field of applied mathematics whose principles and methods are used to solve quantitative problems in disciplines including physics, biology, engineering, and economics. technology. As a leader in the field of form and formulation sciences, TransForm has revolutionized the industry's approach to drug development. Our capabilities are broadly applicable to pharmaceutical products across the entire development and commercialization value chain - from early development to late stage lifecycle management. We have partnered our expertise with several large pharmaceutical companies including Alza, Lilly, Johnson and Johnson, Abbott and Roche to enable or enhance their drug candidates. In research and development, TransForm works with its partners to help them enable challenging development candidates as well as to assist them in making more effective candidate selection decisions which result in reduced attrition rates Noun 1. attrition rate - the rate of shrinkage in size or number rate of attrition rate - a magnitude or frequency relative to a time unit; "they traveled at a rate of 55 miles per hour"; "the rate of change was faster than expected" , development time and cost. For later stage and marketed products, TransForm works with its partners to enhance the commercial value of these products by rapidly discovering novel forms and/or formulations that improve bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration. bi·o·a·vail·a·bil·i·ty n. , broaden intellectual property protection, and enable new indications. TransForm is leveraging its capabilities into medicated medicated /med·i·cat·ed/ (med´i-kat?id) imbued with a medicinal substance. medicated contains a medicinal substance. devices and biologics. In addition to several successful partnered programs, TransForm is applying its novel capabilities to developing a proprietary product pipeline to achieve its mission of becoming an emerging pharmaceutical company. More information on TransForm can be found at: www.transformpharma.com. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion